News & Events:ZSAN

Zosano Pharma Corp (ZSAN): * EMERGEX VACCINES ANNOUNCES SUCCESSFUL COATING OF ITS NOVEL CD8+ T CELL ADAPTIVE COVID-19 VACCINE ONTO ZOSANO PHARMA'S MICRO-NEEDLE PATCH. * EMERGEX - CO, ZOSANO HAVE SHOWED CO'S COVID-19 VACCINE IS STABLE ON PATCHES OVER A WIDE TEMP RANGE FOR UP TO 6 MONTHS AT 40C/75% RELATIVE HUMIDITY Source text for Eikon: Further company coverage:

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Zosano Pharma reported its Q1 earnings results on Friday, May 13, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Zosano Pharma reported in-line EPS of $-1.75 versus an estimate of $-1.75. Revenue was down $126.00 thousand from the same period last year. Last quarter the company missed on EPS by $0.7 which was followed by a 9.16% drop in the share price the next day.

Zosano Pharma Corp (ZSAN): * Zosano Pharma Corp (ZSAN)- ON MAY 10 JOSEPH "JAY" P. HAGAN TENDERED HIS RESIGNATION AS DIRECTOR OF BOARD AND AS CHAIRPERSON OF THE AUDIT COMMITTEE OF BOARD. * Zosano Pharma Corp (ZSAN)- BOARD APPROVED DECREASING THE SIZE OF THE BOARD TO FIVE MEMBERS Further company coverage:

Zosano Pharma Corp (ZSAN): * ZOSANO PHARMA REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS. * Q1 LOSS PER SHARE $7.86. * WILL NEED SUBSTANTIAL ADDITIONAL FUNDING TO FUND ITS OPERATIONS. * WILL NOT BE ABLE TO CONTINUE AS A GOING CONCERN IF IT IS UNABLE TO RAISE ADDITIONAL FUNDS. * AS OF MAY 11, 2022, COMPANY HAD APPROXIMATELY $9.9 MILLION OF CASH AND CASH EQUIVALENTS.

Zosano Pharma Corporation , a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2022. Zosano reported a net loss for the first quarter of 2022 of $33.4 million, or $7.86 per share on a basic and diluted basis, compared with a net loss of $8.1 million, or $2.73 per share on a basic and diluted basis, for the same quarter in 2021.

According to data from Benzinga Pro, during Q4, Zosano Pharma's reported sales totaled $87.00 thousand. Earnings data without context is not clear and can be difficult to base trading decisions on. It is important to keep in mind that ROCE evaluates past performance and is not used as a predictive tool.

81 Biggest Movers From Yesterday

66 Biggest Movers From Yesterday

U.S. stocks traded mostly lower midway through trading, with the Dow Jones dropping more than 100 points on Monday. The Dow traded down 0.42% to 32,837.09 while the NASDAQ rose 0.03% to 12,338.47. The S&P also fell, dropping, 0.39% to 4,115.72. Also check this: Executives Buy Around $1.6M Of 4 Penny Stocks Leading and Lagging Sectors Communication services shares climbed 1.9% on Monday.

31 Stocks Moving In Monday's Mid-Day Session

Zosano Pharma Announces Additional Workforce Layoff

  This article was generated by Benzinga's automated content engine and reviewed by an editor.

Don't forget to check out our premarket coverage here .

Zosano Pharma Corp (ZSAN): * ZOSANO PHARMA PROVIDES CORPORATE UPDATE. * Zosano Pharma Corp (ZSAN) - RECENTLY IMPLEMENTED AN ADDITIONAL WORKFORCE REDUCTION IMPACTING APPROXIMATELY 40% OF ITS REMAINING EMPLOYEES. * Zosano Pharma Corp (ZSAN) - IN ORDER TO PRESERVE ITS CAPITAL AND CASH RESOURCES, ZOSANO HAS SUSPENDED ITS M207 PROGRAM.

Zosano Pharma Corporation , a clinical-stage biopharmaceutical company, today provided a corporate update. On April 14, 2022, the Food and Drug Administration granted Zosano a twelve-month extension to April 20, 2023 to resubmit its M207 New Drug Application.

Don't forget to check out our premarket coverage here .

This article was generated by Benzinga's automated content engine and reviewed by an editor.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Zosano Pharma Corp (ZSAN): * ZOSANO PHARMA ANNOUNCES REVERSE STOCK SPLIT EFFECTIVE TODAY. * Zosano Pharma Corp (ZSAN) - BOARD OF DIRECTORS HAS APPROVED A 1-FOR-35 REVERSE STOCK SPLIT OF COMPANY'S COMMON STOCK. * Zosano Pharma Corp (ZSAN) - REVERSE STOCK SPLIT WILL BECOME EFFECTIVE TODAY, APRIL 11, 2022.